Abstract
Rationale
The 5-HT2C receptor subtype has been implicated extensively in the regulation of ingestive behaviour.
Objective
To assess whether chronic administration of the preferential 5-HT2C receptor agonist, mCPP, reduces rat body weight gain and to determine if this effect is wholly or partially attributable to the effect of the drug on daily food intake.
Methods
Animals were orally dosed with mCPP (10 mg/kg P.O., b.i.d.) or d-fenfluramine (2.5 mg/kg P.O., b.i.d.) for 28 days. Further groups of animals received drug treatments for the first 14 days and then received vehicle for the remainder of the experiment. Locomotor activity was assessed on days 2, 14, and 28. In a second study, animals received mCPP or d-fenfluramine for a 14-day period (dose and route were identical to the previous study). A group of pair-fed controls were included to determine whether the effects on body weight gain were attributable entirely to drug-induced hypophagia.
Results
Both mCPP and d-fenfluramine reduced body weight relative to vehicle-treated controls over the 28-day period. Withdrawal of the drugs on day 14 resulted in a significant rebound weight gain. Neither mCPP nor d-fenfluramine induced significant changes in locomotor activity compared to controls on any of the days tested (2, 14 or 28). In the second, 14-day study, changes in the body weights of pair-fed controls closely paralleled those of their drug-treated counterparts.
Conclusion
These data indicate that chronic oral treatment with mCPP and d-fenfluramine significantly reduces rat body weight gain, an effect that is reversible upon withdrawal and wholly attributable to maintained hypophagia.
Similar content being viewed by others
References
Bickerdike MJ, Vickers SP, Dourish CT (1999) 5-HT2C receptor modulation and the treatment of obesity. Diabetes Obes Metab 1:207–214
Blundell JE, Halford JCG (1998) Serotonin and appetite regulation. CNS Drugs 9:473–495
Clifton PG, Lee MD, Dourish CT (2000) Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152:256–267
Dourish CT (1995) Multiple serotonin receptors: opportunities for new treatments for obesity. Obesity Res 3:S449–S462
Freo U, Holloway HW, Greig NH, Soncrant T (1992) Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioural and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin. Psychopharmacology 107:3038
Grignaschi G, Samanin R (1992) Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur J Pharmacol 212:137–142
Gundlah C, Martin KF, Heal DJ, Auerbach SB (1997) In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 283: 581–591
Hartley JE, Brown G, Fletcher A, Dourish CT (1995) Evidence for the involvement of 5-HT2C receptors in mediating fenfluramine-induced anorexia in rats. Br J Pharmacol 114:373P
Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JG, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK (2002) Activation of central melanocortin pathways by fenfluramine. Science 297:609–611
Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71:691–700
Higgins GA, Ouagazzal AM, Grottick AJ (2001) Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine. Br J Pharmacol 133:459–466
Kennedy AJ, Gibson EL, O'Connell MT, Curzon G (1993) Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Br J Pharmacol 113:262–268
Kennett GA (1993) 5-HT1C receptors and their therapeutic relevance. Curr Opin Invest Drugs 2:317–362
Kennett GA (1998) 5-HT drugs and eating disorders. Drugs 1:456–470
Kennett GA, Curzon G (1988) Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors. Psychopharmacology 96:93–100
Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R (1998) Absence of fenfluramine-induced anorexia and reduced c-fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci 18:5537–5544
Martin GR, Humphrey PPA (1994) Receptors of 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33:261–273
Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924
Neill JC, Cooper SJ (1989) Evidence that d-fenfluramine anorexia is mediated by 5-HT1 receptors. Psychopharmacology 97:213–218
Porter RHP, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128:1320
Preston E, Ma S, Haas N (1990) Ambient temperature modulation of fenfluramine-induced thermogenesis in the rat. Neuropharmacology 29:277–283
Rothwell NJ, Stock MJ (1987) Effect of diet and fenfluramine on thermogenesis in the rat: possible involvement of serotonergic mechanisms. Int J Obes 11:319–324
Rowland NE, Robertson K, Lo J, Rema E (2001) Cross tolerance between anorectic and induction of Fos-ir with dexfenfluramine and 5-HT1B/2C agonists in rats. Psychopharmacology 156:108–114
Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309–312
Sills MA, Lucki I, Frazer A (1985) Development of selective tolerance to the serotonin behavioural syndrome and suppression of locomotor activity after repeated administration or either 5-MeODMT or mCPP. Life Sci 36:2463–2469
Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374:542–546
Trail B, Bright F, Lightowler SL, Kennett GA (1998) Effects of selective 5-HT1B ligands on appetite control in the rat. Br J Pharmacol 123:238P
Vickers SP, Clifton PG, Dourish CT, Tecott LH (1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143:309–314
Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA, Dourish CT (2000) Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 130:1305–1314
Vickers SP, Easton NE, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA (2001a) Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists. Pharmacol Biochem Behav 69:643–652
Vickers SP, Dourish CT, Kennett GA (2001b) Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41:200–209
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vickers, S.P., Easton, N., Webster, L.J. et al. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167, 274–280 (2003). https://doi.org/10.1007/s00213-002-1378-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-002-1378-6